Clinical trials: Hepatitis B, Chronic
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety…
- Trial name
- NCT02952924
- Testing
- Midazolam, RO7049389
- Where
- 21 sites in Australia, Bulgaria and 6 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
- Trial name
- NCT04749368
- Testing
- BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-α, BRII-179 (VBI-2601)
- Where
- 28 sites in Australia, China and 4 more
- Volunteers
- 91 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
- Trial name
- NCT05001022
- Testing
- ALG-020572
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Chronic Hepatitis B
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in…
- Trial name
- NCT02932150
- Testing
- TAF
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
HBeAg(+) Chronic Hepatitis B
A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)
A study to evaluate the efficacy and safety of clevudine and peg-interferon in sequence compared with clevudine alone in the patients with HBeAg(+) chronic Hepatitis B or clevudine and peg-interferon sequential treatment in…
- Trial name
- NCT01264367
- Testing
- Clevudine, Clevudine + Peg-interferon
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis b
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy.
- Trial name
- NCT05760781
- Testing
- STSG-0002 Injection
- Where
- 4 sites in China
- Volunteers
- 9 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis B
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment.
- Trial name
- NCT00132652
- Testing
- Lamivudine, Telbivudine
- Where
- 14 sites in United States, Australia and 9 more
- Volunteers
- 240 people
- Sponsor
- Novartis
Chronic Hepatitis B
Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets
This study was a single-center study, including randomized, double-blind, placebo-controlled, single-dose escalation study, multiple-dose study, food effect on pharmacokinetics and drug metabolism transformation study, drug…
- Trial name
- NCT06431438
- Testing
- TQA3810
- Where
- China
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis B
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy
- Trial name
- NCT01037062
- Testing
- Entecavir
- Where
- 48 sites in Japan
- Volunteers
- 282 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis b
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.
- Trial name
- RUBY (NCT06989788)
- Testing
- AVX70371
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Hepatitis B, Chronic
A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant…
- Trial name
- Piranga (NCT04225715)
- Testing
- Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531)
- Where
- 33 sites in Bulgaria, Canada and 11 more
- Volunteers
- 281 people
- Sponsor
- Hoffmann-La Roche
For Treatment of Chronic Hepatitis B Virus Infection
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase…
- Trial name
- NCT06491563
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 12 sites in China
- Volunteers
- 150 people
- Sponsor
- Brii Biosciences Limited
Non-alcoholic Steatohepatitis, Chronic Liver Disease
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive…
- Conditions
- Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis
- Trial name
- ELEVATE (NCT00678587)
- Testing
- Eltrombopag
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
HBV Infection
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of…
- Trial name
- NCT07179653
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Hepatitis B, Chronic
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B.
- Trial name
- NCT02598063
- Testing
- Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a
- Where
- 12 sites in China, Hong Kong
- Volunteers
- 255 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
This observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis B who have failed antiviral treatment with nucleoside (nucleotide) analogues.
- Trial name
- NCT01794234
- Where
- 9 sites in Poland
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
The purpose of this study is to assess antiviral activity when administered alone for 3 days or in combination with peginterferon and ribavirin for 12 weeks.
- Trial name
- NCT00911963
- Testing
- peginterferon alfa-2a, ribavirin
- Where
- 10 sites in United States, Argentina and 2 more
- Volunteers
- 49 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis B
Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection
The primary objective of this study is to characterize the long term (ie, 96 weeks of follow up) bone safety profile of open-label tenofovir disoproxil fumarate (tenofovir DF) treatment in CHB-infected adolescents.
- Trial name
- NCT02479880
- Testing
- Tenofovir DF, DEXA Scan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
This study is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.
- Trial name
- NCT06993480
- Testing
- AHB-137
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ausper Biopharma Co., Ltd.